View the original post from U of U Health here.
In a rare but serious complication of cancer, the body’s immune system attacks the brain, causing rapid-onset memory loss and cognitive deficits. What triggered this sudden biological civil war was largely unknown.
Now, researchers at University of Utah Health have found that some tumors can release a protein that looks like a virus, kickstarting an out-of-control immune reaction that may damage brain cells.
Left to right: Junjie Xu, Stacey Clardy and Jason Shepherd. Photo credits: Junjie Xu (left), Charlie Ehlert (center and right).
Rapid immune assault
The swift escalation of symptoms—which can include memory and behavioral changes, loss of coordination and even seizures—is a hallmark of the disease, called anti-Ma2 paraneoplastic neurological syndrome, according to Jason Shepherd, associate professor of neurobiology and co-author of the study published Jan. 31 in Cell. The disease is one of a group of cancer-related neurological syndromes that occur in less than one in 10,000 people with cancer. Symptoms of these diseases vary, but all involve rapid immune reactions targeting the nervous system.
“Most patients begin to experience these unusual neurologic symptoms before they even know they have a cancer,” said neurologist Stacey L. Clardy, a coauthor on the study.
These rapid-onset symptoms are the result of the immune system suddenly striking specific proteins in the brain. Scientists knew that this flare of immunity often targets a protein called PNMA2. But nobody knew why PNMA2 provokes such a strong immune response, which left doctors at a loss for ways to prevent it.
“We do not understand what is happening at the cellular or molecular level to actually cause the syndrome,” Clardy said, “and understanding the mechanism of disease is crucial to developing better treatments.”
The new research illustrates how tumor cells can manipulate their environment, according to Neli Ulrich, executive director of the Comprehensive Cancer Center at the U’s Huntsman Cancer Institute and a Jon M. and Karen Huntsman Presidential Professor in Cancer Research.
“We hope that this innovative transdisciplinary research will positively impact both the lives of cancer patients and of those who experience neurological symptoms,” she said.
A virus lookalike in the wrong place, at the wrong time
To figure out how PNMA2 triggers an immune reaction, lead author Junjie Xu, a graduate researcher in neurobiology, examined the protein’s structure using advanced microscopy. When he saw the first clear image of the protein, he was “so, so excited,” Xu said. Multiple PNMA2 proteins had spontaneously self-organized into 12-sided complexes that bore a striking resemblance to the geometric protein shells of some viruses.
Left: the three-dimensional structure of a PNMA2 complex, which can trigger a dangerous immune reaction when released by tumor cells. Image credit: Junjie Xu. Right: artist’s depiction of an adenovirus, which can cause cold- and flu-like symptoms. Image credit: Getty Images.
One of the immune system’s healthy functions is to attack viruses, and PNMA2’s virus-like structure makes it particularly prone to being targeted as well, the researchers found. In fact, in experiments in mice, the immune system only attacked PNMA2 protein when it was assembled into virus-like complexes. The location of PNMA2 in the body is also a crucial piece of the puzzle, the scientists found.
“This protein normally is only expressed in the brain, in neurons,” Xu said, “but some cancer cells can express it, which can trigger an immune response.”
As long as PNMA2 stays in the brain, the immune system won’t react to it. But on a rare occasions, a tumor elsewhere in the body will start producing PNMA2 protein. And when the immune system detects PNMA2 protein outside the brain, it reacts like it would to any foreign invader. The immune system makes antibodies that bind to the unfamiliar substance, and those antibodies direct immune cells to attack.
But once activated, the immune system doesn’t just attack the PNMA2 produced by the cancer. It also targets the parts of the brain that produce PNMA2 normally, including regions involved in memory, learning and movement. The brain normally has a degree of protection from the immune system, but cancer weakens that barrier, leaving the brain vulnerable to this immune onslaught.
In future work, the researchers aim to figure out which aspect of the immune response leads to patients’ rapid cognitive decline—the antibodies themselves, immune cells making their way into the brain, or some combination of the two.
Understanding how the immune system causes neurological symptoms may help scientists design targeted treatments.
“If we show that PNMA2 antibodies are the culprit that really drives the neurological symptoms, you could devise a way to block those antibodies from getting into the brain or mop them up with something as a treatment,” Shepherd said. “If you can alleviate some of those neurological symptoms, it really would be huge.”